前列地尔联合替米沙坦治疗糖尿病肾病合并肾癌蛋白尿的效果观察

Effect of alprostadil combined with telmisartan on proteinuria in patients with diabetic nephropathy and renal cell carcinoma

目的探讨前列地尔联合替米沙坦治疗糖尿病肾病合并肾癌蛋白尿的临床效果。方法分析我院2014-2-2016-12收治的64例糖尿病肾病合并肾癌蛋白尿患者的临床资料,随机分为观察组和对照组,各32例,对照组患者给予替米沙坦进行治疗,观察组患者前列地尔联合替米沙坦治疗,观察两组患者的临床治疗效果。结果观察组治疗的总有效率为96.87%;对照组治疗的总有效率为75%,观察组并发症发生率为3.13%,对照组并发症发生率为12.5%,观察组患者治疗的效果明显优于对照组,差异具有统计学意义均(P<0.05)。结论前列地尔联合替米沙坦治疗糖尿病肾病合并肾癌蛋白尿的临床效果较好,值得进一步的研究和在临床上推广应用。

OBJECTIVE To investigate the clinical effect of alprostadil combined with telmisartan in the treatment of proteinuria in patients with diabetic nephropathy and renal cell carcinoma.METHODS The clinical data of 64 patients admitted to our hospital patients with diabetic nephropathy were randomly divided into observation group and control group,the control group were treated with telmisartan treatment,the observation group were alprostadil combined with telmisartan treatment,observation clinical outcomes between the two groups.RESULTS The treatment of the total effective rate96.87%;the control group,the total effective rate of 75% was observed complication rate was 3.13% in the control group,the complication rate was 12.5%,the treatment effect the observation group were significantly better than the control group,the difference was statistically significant(P<0.05).CONCLUSIONS The clinical effect of alprostadil combined with telmisartan in the treatment of diabetic nephropathy with renal cancer proteinuria is better.It is worthy of further study and clinical application.